PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT02997163
- Locations
- πΊπΈ
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
πΊπΈKarmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
πΊπΈRobert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT02997176
- Locations
- πΊπΈ
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States
πΊπΈUCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
πΊπΈUCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States
Korean Post-marketing Surveillance for Xeljanz
- Conditions
- Rheumatoid ArthritisPsoriatic Arthritis
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1041
- Registration Number
- NCT02984020
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
π°π·Kyung Hee University Hospital at Gangdong / Rheumatology, Seoul, Gangdong-gu, Korea, Republic of
π°π·Chonbuk National University Hospital, Department of Rheumatology, Chonju, Chonbuk, Korea, Republic of
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 142
- Registration Number
- NCT02974868
- Locations
- πΊπΈ
Yale Hearing and Balance Center, New Haven, Connecticut, United States
πΊπΈYale School of Medicine, New Haven, Connecticut, United States
πΊπΈYale New Haven Hospital, New Haven, Connecticut, United States
PF-06741086 Multiple Dose Study in Severe Hemophilia
- Conditions
- Hemophilia A or B
- Interventions
- Biological: PF-06741086
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02974855
- Locations
- π¨π±
Hospital Dr. Sotero del Rio, Santiago, Chile
ππ·Klinicki bolnicki centar Zagreb, Zagreb, Croatia
πΊπΈRush University Medical Center, Chicago, Illinois, United States
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT02974374
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT02969044
- Locations
- πΊπΈ
Clayton Medical Associates, PC, Saint Louis, Missouri, United States
πΊπΈCalifornia Medical Research Associates Inc., Northridge, California, United States
πΊπΈAltoona Center For Clinical Research, Duncansville, Pennsylvania, United States
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT02969018
- Locations
- πΊπΈ
Center for Clinical Studies, Houston, Texas, United States
π¨π¦Lynderm Research Inc, Markham, Ontario, Canada
πΊπΈDawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 319
- Registration Number
- NCT02958865
- Locations
- πΊπΈ
Dothan Surgery Center, Dothan, Alabama, United States
πΊπΈGut P.C., dba Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
πΊπΈSouthern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En-, Los Angeles, California, United States
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
- Conditions
- Non-Interventional Study
- Interventions
- Other: Overall satisfaction questionnaires of home use of Nivestim
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 171
- Registration Number
- NCT02956967
- Locations
- π©πͺ
Office of Albrecht Kretzschmar, Leipzig, Germany
π©πͺOffice of Nidal Gazawi, Leipzig, Germany
π©πͺCampus Charite Mitte, Med. Klinik m. Schwerpunkt Haematologie und Onkologie, Berlin, Germany